Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

The cost of prescription drugs is set to climb in 2025 and beyond, according to TD Cowen’s 30th Annual Drug Pricing survey.

Top Medicare Part D drugs without price negotiations have seen a 98% increase in list prices since their launch. Read more ...

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...

AARP’s new research finds price growth for top Part D prescription drugs has exceeded inflation, making a case for allowing ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...

Drug pricing is influenced by numerous factors, but technology has the potential to strike the critical balance between ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate ...

Findings show the impact of drug companies’ relentless price increases, underscoring the importance of the changes included ...

Cochair of our recent Institute for Value-Based Medicine® event hosted with NYU Langone Health, Oscar B. Lahoud, MD, speaks ...

Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs.

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things to look for include more widespread adoption of artificial intelligence ...